Patents and innovation in cancer therapeutics: Lessons from CellPro

被引：22

作者：

Bar-Shalom, A ^{[1
]}

Cook-Deegan, R ^{[1
]}

机构：

[1] Duke Univ, Ctr Genome Eth Law & Policy, Durham, NC 27708 USA

来源：

MILBANK QUARTERLY | 2002年 / 80卷 / 04期

关键词：

D O I：

10.1111/1468-0009.00027

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

This article discusses the interaction between intellectual property and cancer treatment. CellPro, developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center. A patent with broad claims to bone marrow stem cell antibodies had been awarded to Johns Hopkins University and licensed to Baxter Healthcare under the 1980 Bayh-Dole Act to promote commercial use of inventions from federally funded research. CellPro got FDA approval more than two years before Baxter but lost patent infringement litigation. NIH elected not to compel Hopkins to license its patents to CellPro. CellPro went out of business, selling its technology to its competitor. Decisions at both firms and university licensing offices, and policies at the Patent and Trademark Office, NIH, and the courts influenced the outcome.

引用

页码：637 / +

页数：42